Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS

Podrobná bibliografie
Hlavní autoři:	Jones, R, Tervaert, J, Hauser, T, Luqmani, R, Peh, C, Savage, C, Segelmark, M, Tesar, V, Van Paassen, P, Walsh, M, Walsh, D, Westman, K, Jayne, D
Médium:	Journal article
Vydáno:	2009

Podobné jednotky

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Autor: Jones, R, a další
Vydáno: (2010)

Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial
Autor: Harper, L, a další
Vydáno: (2009)

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Autor: Harper, L, a další
Vydáno: (2012)

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
Autor: Roberta Fenoglio, a další
Vydáno: (2020-10-01)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
Autor: Frank B. Cortazar, a další
Vydáno: (2018-03-01)

Cardiovascular outcomes in ANCA associated vasculitis
Autor: Mukhtyar, C, a další
Vydáno: (2008)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
Autor: Luqmani, R, a další
Vydáno: (1999)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
Autor: Yates, M, a další
Vydáno: (2016)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
Autor: Renée Ysermans, a další
Vydáno: (2023-01-01)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Autor: Yates, M, a další
Vydáno: (2016)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
Autor: Yates, M, a další
Vydáno: (2016)

Long-term patient survival in ANCA-associated vasculitis
Autor: Flossmann, O, a další
Vydáno: (2011)

Long-term patient survival in ANCA-associated vasculitis.
Autor: Flossmann, O, a další
Vydáno: (2011)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
Autor: Suppiah, R, a další
Vydáno: (2011)

Long-term patient survival in ANCA-associated vasculitis.
Autor: Flossmann, O, a další
Vydáno: (2011)

Long-term survival of ANCA-associated vasculitis
Autor: Flossmann, O, a další
Vydáno: (2009)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
Autor: Yew, S, a další
Vydáno: (2012)

Diagnosis and management of ANCA associated vasculitis.
Autor: Berden, A, a další
Vydáno: (2012)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
Autor: Yates, M, a další
Vydáno: (2017)

Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials
Autor: Walsh, M, a další
Vydáno: (2009)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
Autor: Yew, S, a další
Vydáno: (2012)

Cyclophosphamide and systemic vasculitis.
Autor: Luqmani, R, a další
Vydáno: (1993)

Damage assessment in ANCA-associated vasculitis.
Autor: Bhamra, K, a další
Vydáno: (2012)

Is rituximab effective for induction of remission in ANCA-associated vasculitis?
Autor: Carmen Rain, a další
Vydáno: (2015-08-01)

Maintenance of clinical remission in ANCA-associated vasculitis.
Autor: Luqmani, R
Vydáno: (2013)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
Autor: Thiel Jens, a další
Vydáno: (2011-11-01)

Outcome measures in ANCA-associated vasculitis.
Autor: Suppiah, R, a další
Vydáno: (2010)

Thyroid disease in ANCA-associated vasculitis: a clinical and epidemiological study
Autor: David Jayne, a další
Vydáno: (2024-07-01)

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report
Autor: O. Psenak, a další
Vydáno: (2021-08-01)

Complement Inhibition in ANCA-Associated Vasculitis
Autor: Vladimir Tesar, a další
Vydáno: (2022-07-01)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
Autor: Luqmani, R
Vydáno: (2013)

Predictors of renal involvement in ANCA associated vasculitis
Autor: Kronbichler, A, a další
Vydáno: (2018)

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Autor: de Groot, K, a další
Vydáno: (2009)

Hypophysitis Secondary to Small Vessel ANCA Vasculitis Treated With Rituximab
Autor: Nankee K. Kumar, AB, a další
Vydáno: (2024-03-01)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
Autor: Luqmani, R, a další
Vydáno: (2007)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
Autor: Suppiah, R, a další
Vydáno: (2011)

Explaining fatigue in ANCA-associated vasculitis
Autor: Basu, N, a další
Vydáno: (2013)

Cutaneous manifestations of ANCA-associated vasculitis
Autor: Chiesafuxench, Z, a další
Vydáno: (2016)

Comparison of disease activity measures for ANCA-associated vasculitis.
Autor: Merkel, P, a další
Vydáno: (2004)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
Autor: Salisbury, E, a další
Vydáno: (2003)